St. Jude faces shareholder suit over Riata; Bard suffers setback in patent suit against Gore;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: Tijuana is now a booming medical device industry cluster. Article | Follow @MarkHFierce

 @DamianFierce: We all know how devicemakers hate the potential 2.3% tax, but might they be exaggerating the pain? News | Follow @DamianFierce

> St. Jude Medical ($STJ) faces a shareholder class action lawsuit for failing to disclose the full extent of the problems with its now-recalled Riata leads, which resulted, the suit alleges, in an inflated share price. Story

> C. R. Bard is facing a partial setback in a patent infringement case against W. L. Gore. The U.S. Court of Appeals for the Federal Circuit has reversed part of its previous ruling awarding $317 million to Bard in the case. Report

> Pittsburgh's ALung got some positive results from clinical trials of the Hemolung respiratory assist system, a respiratory dialysis system designed to treat COPD. More

> T2 Biosystems is preparing to present data on its new endotoxin-detecting assay for injectables at the American Society for Microbiology General Meeting this week in San Francisco. Release

Biotech News

 @FierceBiotech: The Fierce team has landed in Boston. Check out our dedicated BIO2012 page. Special Coverage | Follow @FierceBiotech

 @JohnCFierce: Quintiles (CRO) is expanding in China, building a regional HQ in Shanghai. Release | Follow @JohnCFierce

 @RyanMFierce: Roche does an encore Alzheimer's deal with AC Immune worth up to $420M, focused on anti-Tau antibodies. More | Follow @RyanMFierce

> BIO's James Greenwood sees industry optimism returning. Report

> Roche snags another Alzheimer's antibody from AC Immune in $418M-plus deal. News

> Ambrx inks $303M 'smart bomb' development pact with Merck. More

> Infinity Pharma writes off lead drug after two more failed studies. Article

Pharma News

 @FiercePharma: China's pharma industry blames toxic capsules on super-aggressive tendering, says corner-cutting won't stop. Report | Follow @FiercePharma

> FDA keeps door open to pharmacy versions of KV's Makena. More

> Biotest prepared to exit Greece for non-payment. Story

> Cipla chief aims for more cut-rate cancer drugs. Article

Biotech IT News

> Harvard IDs key human-hosted bugs with computer systems. More

> Third Rock fuels $41M launch of Bay Area biotech. Item

> Africa goes mobile to tackle drug safety woes. Story

And Finally... Minnesota, with its huge stake in the medical devices industry, has become something of a ground zero for debate over the proposed 2.3% tax. Last week, a member of a local biotech trade group wrote an anti-tax editorial in the Star Tribune. This week, the publisher of a Minnesota-based health website called his claims "outlandish." News

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.